Lineage Cell Therapeutics Inc. (LCTX) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Lineage Cell Therapeutics Inc. (NYSE: LCTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $1.00 (-2.91% 1D, market cap $252.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LCTX ranks #980 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LCTX carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CABA (Cabaletta Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M) and FATE (Fate Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $249.2M). Among the 5-stock peer group, LCTX leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).
Per LCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000876343), Lineage Cell Therapeutics Inc. generated $14.6M in revenue (+53.2% YoY), -$63.5M in net income, and -$19.4M in free cash flow against $112.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While LCTX currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.01) and Max Pain ($1.05) forces dealer call-delta covering toward $2.19.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Lineage Cell Therapeutics Inc. (LCTX) dropped -2.91% to $1.00, trading at 10% of its 52-week range ($0.88 – $2.09). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance UK report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +53.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LCTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LCTX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Lineage Cell Therapeutics Inc. (LCTX) ranks #980 by composite RQD confidence (20/100, grade E) and #539 by equity capitalization ($252.9M). Within this direct 5-issuer industry benchmark cohort, LCTX leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with LCTX at 20/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LCTX
ACTIVE
Lineage Cell Therapeutics Inc. | E | 20/100 | — | — | -35.0% | -2.91% | $252.9M | Benchmark Subject |
| CABA Cabaletta Bio Inc. | E | 33/100 | — | — | -35.0% | -4.73% | $256.0M | /caba-vs-lctx → |
| FATE Fate Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -4.15% | $249.2M | /fate-vs-lctx → |
| LXEO Lexeo Therapeutics Inc. | E | 33/100 | — | — | -35.0% | +2.61% | $257.6M | /lxeo-vs-lctx → |
| IPSC Century Therapeutics Inc. | E | 18/100 | — | — | -14.1% | +0.69% | $266.2M | /ipsc-vs-lctx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lineage Cell Therapeutics Inc. (LCTX) reported GAAP revenue of $14.6M (+53.2% vs. FY2024 revenue of $9.5M , and +62.7% cumulative change since FY2023) , GAAP net income of -$63.5M, operating cash flow of -$18.9M, and free cash flow of -$19.4M (+17.8% YoY). On the balance sheet, LCTX closed FY2025 with $112.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $14.6M | -$63.5M | -$18.9M | -$19.4M | $112.6M | — |
| FY2024 (FY) | 2024-12-31 | $9.5M | -$18.6M | -$23.1M | -$23.7M | $113.2M | — |
| FY2023 (FY) | 2023-12-31 | $8.9M | -$21.5M | -$28.6M | -$28.6M | — | — |
As of 2026-11-03, Lineage Cell Therapeutics Inc. (NYSE: LCTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $1.00 (-2.91% 1D, market cap $252.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LCTX ranks #980 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LCTX carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CABA (Cabaletta Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M) and FATE (Fate Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $249.2M). Among the 5-stock peer group, LCTX leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).
Per LCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000876343), Lineage Cell Therapeutics Inc. generated $14.6M in revenue (+53.2% YoY), -$63.5M in net income, and -$19.4M in free cash flow against $112.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
LCTX last traded at $1.00 (-2.91% on volume of 1,166,448 shares), positioning the stock -0.99% below its 50-day simple moving average ($1.01) and -24.24% below its 200-day simple moving average ($1.32). Across its 52-week range of $0.88 to $2.09, LCTX sits at the 9.9% percentile with a 14-day RSI of 50.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.13).
Why LCTX Stock dropped -2.91% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, LCTX receives an RQD Score of 22, letter grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows: Fundamental Cash Engine 5/20 (ROIC -35%; FCF yield -7.46%), Whale 13F Flow 8/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 4/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 2/20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are the forensic balance sheet and insider conviction, which the rating treats as the primary risk signals. The strongest relative pillar, institutional flow at 8/20, still sits well below a neutral midpoint. Upside drivers are limited in the source data to the rating's institutional positioning component; the valuation tradeoff is that a $1.03 share price is paired with negative ROIC and negative free-cash-flow yield, leaving little cash-generation support for the equity. The rating's overall message is that the forensic and cash-engine pillars dominate the picture.
Per the company profile, Lineage Cell Therapeutics Inc. is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile does not describe its products, customers, or revenue model. The SEC financials show reported revenue of $14.6M for FY 2025, but the source data does not identify the revenue sources. Market capitalization is listed as $0.3B in the profile and $260.5M in market data.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $14.6M | $-36.6M | $-63.5M | N/A | $-19.4M | $40.8M | N/A |
| FY 2024 | $9.5M | $-21.5M | $-18.6M | N/A | $-23.7M | $45.8M | N/A |
| FY 2023 | $8.9M | $-24.7M | $-21.5M | N/A | $-28.6M | N/A | N/A |
Per the SEC financials, operating and net losses appear in every reported period, and the FY 2025 net loss of $-63.5M is the largest of the three. Per the market data, gross margin is 0%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash declined from $45.8M in FY 2024 to $40.8M in FY 2025 against negative free cash flow in each period.
Per the recent news feed, six items reference LCTX. Five are marked YELLOW under the "Market Wire" label, consisting of Yahoo Finance UK, TradingView, and Benzinga items on market action and an earnings call transcript for Q2 2026. One item from www.marketscreener.com is marked RED under the "Risk Watch" label and is headlined "Lineage Cell Therapeutics Provides Update On ReSonance Program For Hearing Loss." The source data does not describe the content of that update. The Butterfly Supply-Chain Graph reports no supply chain links and no proprietary signals.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is the Health Care classification and the Biological Products industry label.
Real-time company headlines, analyst actions, and sector developments for Lineage Cell Therapeutics Inc. (LCTX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance UK report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.
Welcome to the LCTX (Lineage Cell Therapeutics Inc.) Roar Pit. Current RQD Composite is 22/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on LCTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Lineage Cell Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on LCTX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.03 (52-wk range $0.88 - $2.09), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).